Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

DOVA - Dova Pharmaceuticals Inc.

Previous close
28.04
28.040   100.000%

Share volume: 0
Last Updated: Mon 11 Nov 2019 10:00:01 PM CET
Pharmaceuticals: Major: -0.03%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
19%
Profitability 2%
Dept financing 50%
Liquidity 41%
Performance 22%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$28.04
P/E Ratio 
N/A
DAY RANGE
$28.04 - $28.04
EPS 
$0.00
52 WEEK RANGE
$5.62 - $28.54
52 WEEK CHANGE
$69.43
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$773,127
AVERAGE 30 VOLUME 
$501,889
Company detail
CEO:
Region: US
Website: http://dova.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Pharmaceuticals: Major
Sector: Health Technology

Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist. The company was founded on March 24, 2016 and is headquartered in Durham, NC.

Recent news